Recent 8-K filings for ACTU

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 11, 2026 21:27 UTC regulatory item 7.01item 9.01

  Actuate Therapeutics receives FDA IND clearance for oral elraglusib Phase 1/2 study

source · ACTU on sec.gov